Aims and Scope
The Etiopathogenesis and Genetic Factors in Idiopathic Inflammatory Myopathies: A Review ArticleGustavo-Esteban Lugo-Zamudio, Rosa-Elda Barbosa-Cobos, Lucía-Verónica Maya-Piña, Dolores Delgado-Ochoa, María-Mercedes López-Mayorga, Ivonne Arenas-Silva and Diana-Sarai Arellano-Álvarez
The Open Rheumatology Journal, 2023; 17: e187431292302140.
Electronic Publication Date: April 05, 2023
Knee Pain Examined under Musculoskeletal Ultrasonography: Experience from a Community-based Rheumatology Practice – A Cross-sectional StudyMd Abu Bakar Siddiq and Mohammad Abdur Rahim
The Open Rheumatology Journal, 2023; 17: e187431292301310.
Electronic Publication Date: March 30, 2023
CLINICAL TRIAL STUDY
KiOmedine® CM-Chitosan is Effective for Treating Advanced Symptomatic Knee Osteoarthritis up to Six Months Following a Single Intra-Articular Injection: A Post Hoc Analysis of Aproove Clinical StudyP.J. Emans, G. Skaliczki, D. Haverkamp, J. Bentin, M. Chausson, M. Schifflers and N. Portelange
The Open Rheumatology Journal, 2023; 17: e187431292302010.
Electronic Publication Date: February 14, 2023
Patient Satisfaction with the Etanercept Biosimilar SB4 Device, Among Rheumatoid Arthritis and Spondyloarthropathy Patients - A German Observational StudyChristof Maucksch, Peer M. Aries, Silke Zinke, Ulf Müller-Ladner
The etanercept biosimilar SB4 is a TNF inhibitor authorised for use as a targeted Biological Disease-Modifying Anti-Rheumatic Drug (bDMARD). Various administration devices have been developed for subcutaneous self-injection of bDMARDs.
This study surveyed patient satisfaction with their experience of using the SB4 pre-filled pen device.
This non-interventional, cross-sectional, multi-centre study enrolled adult rheumatoid arthritis and spondyloarthropathy patients who had been treated for at least three months with the SB4 pre-filled pen. Based on a standardized questionnaire, patients rated general satisfaction, handling, user-friendliness, physical characteristics, and training material received. A total of 492 eligible patients completed questionnaires at 43 centres across Germany between August 2017 and June 2018. Data were analysed descriptively. Pre-defined subgroup analyses by previous therapy and by indication were performed.
Overall, 87% (95% CI 83% - 90%) of patients reported being ‘satisfied’ or ‘very satisfied’ with the pen. 89% of patients reported that the pen was ‘simple’ or ‘very simple’ to use. Most patients (87%) self-injected. 93% of patients who received training on the use of the pen were ‘satisfied’ or ‘very satisfied’ with the training provided. In this cross-sectional study, 12 patients reported an Adverse Event (AE) and one patient reported a treatment-related AE (nausea).
The results demonstrated a high level of general satisfaction among patients using the SB4 pre-filled pen as well as satisfaction with ease of use for patients who were either naïve to bDMARDs or who had switched to SB4 from other bDMARDs.
July 21, 2020
- October 24, 2017
Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA StudySeptember 30, 2017
SLE and Serum Complement: Causative, Concomitant or Coincidental?September 30, 2017
Predictor of the Simplified Disease Activity Index 50 (SDAI 50) at Month 3 of bDMARD Treatment in Patients with Long-Established Rheumatoid ArthritisJuly 27, 2017
Is Male Rheumatoid Arthritis an Occupational Disease? A ReviewJune 29, 2017
Predictive Value of Serum Infliximab Levels at Induction Phase in Rheumatoid Arthritis PatientsMay 31, 2017
Biological Effects of Phosphocitrate on Osteoarthritic Articular Chondrocytes